JP2024081718A5 - - Google Patents

Download PDF

Info

Publication number
JP2024081718A5
JP2024081718A5 JP2024049655A JP2024049655A JP2024081718A5 JP 2024081718 A5 JP2024081718 A5 JP 2024081718A5 JP 2024049655 A JP2024049655 A JP 2024049655A JP 2024049655 A JP2024049655 A JP 2024049655A JP 2024081718 A5 JP2024081718 A5 JP 2024081718A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
nos
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024049655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024081718A (ja
JP7804715B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/023382 external-priority patent/WO2019183362A1/en
Application filed filed Critical
Publication of JP2024081718A publication Critical patent/JP2024081718A/ja
Publication of JP2024081718A5 publication Critical patent/JP2024081718A5/ja
Application granted granted Critical
Publication of JP7804715B2 publication Critical patent/JP7804715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024049655A 2018-03-21 2024-03-26 Fcバリアント組成物およびその使用方法 Active JP7804715B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862646053P 2018-03-21 2018-03-21
US62/646,053 2018-03-21
PCT/US2019/023382 WO2019183362A1 (en) 2018-03-21 2019-03-21 Fc variant compositions and methods of use thereof
JP2020550791A JP7551499B2 (ja) 2018-03-21 2019-03-21 Fcバリアント組成物およびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020550791A Division JP7551499B2 (ja) 2018-03-21 2019-03-21 Fcバリアント組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2024081718A JP2024081718A (ja) 2024-06-18
JP2024081718A5 true JP2024081718A5 (cg-RX-API-DMAC7.html) 2024-10-15
JP7804715B2 JP7804715B2 (ja) 2026-01-22

Family

ID=67988040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550791A Active JP7551499B2 (ja) 2018-03-21 2019-03-21 Fcバリアント組成物およびその使用方法
JP2024049655A Active JP7804715B2 (ja) 2018-03-21 2024-03-26 Fcバリアント組成物およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020550791A Active JP7551499B2 (ja) 2018-03-21 2019-03-21 Fcバリアント組成物およびその使用方法

Country Status (5)

Country Link
US (2) US20210070860A1 (cg-RX-API-DMAC7.html)
EP (1) EP3768315A4 (cg-RX-API-DMAC7.html)
JP (2) JP7551499B2 (cg-RX-API-DMAC7.html)
AU (2) AU2019240247B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019183362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6932700B2 (ja) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
CN113061192B (zh) * 2021-04-12 2023-08-22 佰思巢(上海)生物科技有限公司 一类对pd-1受体具有高亲和力的pdl1融合蛋白及其作为t细胞抑制剂的应用
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
ES2573642T3 (es) * 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
CA2826467C (en) * 2011-02-07 2019-11-12 Research Development Foundation Engineered immunoglobulin fc polypeptides
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
WO2013002362A1 (ja) * 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
CA2871934C (en) * 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
WO2016033509A1 (en) 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
US20170362324A1 (en) * 2014-09-12 2017-12-21 Biogen Ma Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof
EP3250602A1 (en) * 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
CA2978501A1 (en) 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
MX2017012805A (es) * 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
CA3031194A1 (en) * 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3494139B1 (en) * 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use

Similar Documents

Publication Publication Date Title
JP2023036899A5 (cg-RX-API-DMAC7.html)
CN116171167B (zh) 包含配体-受体对和生物功能蛋白的融合蛋白
US11382963B2 (en) Engineered T cells and uses therefor
WO2020047299A1 (en) Multi-chain chimeric polypeptides and uses thereof
AU2018387741B2 (en) FC binding fragments comprising a PD-L1 antigen-binding site
US20210077576A1 (en) Combination tumor treatment with an integrin-binding-fc fusion protein and immune stimulator
RU2018108236A (ru) Слитые белки на основе gitrl и пути их применения
US10350266B2 (en) Method of treating cancer with a multiple integrin binding Fc fusion protein
US20210015870A1 (en) Bcma-car-t cells
Müller et al. A novel antibody–4-1BBL fusion protein for targeted costimulation in cancer immunotherapy
JP2018522571A5 (cg-RX-API-DMAC7.html)
CN112955172A (zh) 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途
JP2020505054A5 (cg-RX-API-DMAC7.html)
RU2016150096A (ru) Белки слияния на основе ox40l и пути их применения
Fellermeier et al. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format
AU2024201211A1 (en) Soluble interferon receptors and uses thereof
CN114302891A (zh) 新的il-10变体蛋白及其用途
US11873348B2 (en) Peptides
WO2020180551A1 (en) Car-t cells with humanized cd19 scfv
CN109897114A (zh) 具有自杀基因开关的靶向cd47的工程化免疫细胞
CA3220872A1 (en) Antibody-nkg2d ligand domain fusion protein
EP4613769A1 (en) Fusion protein and use thereof
US12528873B2 (en) Humanized BCMA antibody and BCMA-CAR-T cells
WO2020112529A1 (en) Car-t cells having humanized cd19 scfv with mutation in cdr 1 region
CA3220875A1 (en) Antibody-nkg2d ligand domain fusion protein